Home Online Features Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
Akeso’s Ebdarokimab ( IL – 12/IL – 23 Dual – Targeted Monoclonal Antibody) Approved in China for Moderate – to – Severe Plaque Psoriasis
Press Releases
April 18, 2025

Akeso’s Ebdarokimab ( IL – 12/IL – 23 Dual – Targeted Monoclonal Antibody) Approved in China for Moderate – to – Severe Plaque Psoriasis

By Akeso, Inc.

HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received

bradford

The Bradford Era

email
Local & Social